These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15125753)

  • 41. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast enlargement in 13 men who were seropositive for human immunodeficiency virus.
    Evans DL; Pantanowitz L; Dezube BJ; Aboulafia DM
    Clin Infect Dis; 2002 Nov; 35(9):1113-9. PubMed ID: 12384846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Manic syndrome associated with efavirenz overdose.
    Blanch J; Corbella B; García F; Parellada E; Gatell JM
    Clin Infect Dis; 2001 Jul; 33(2):270-1. PubMed ID: 11418896
    [No Abstract]   [Full Text] [Related]  

  • 44. Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: four cases and a review of the literature.
    Benveniste O; Simon A; Herson S
    Clin Infect Dis; 2001 Sep; 33(6):891-3. PubMed ID: 11512095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 46. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
    Fischl MA; Ribaudo HJ; Collier AC; Erice A; Giuliano M; Dehlinger M; Eron JJ; Saag MS; Hammer SM; Vella S; Morse GD; Feinberg JE; Demeter LM; Eshleman SH;
    J Infect Dis; 2003 Sep; 188(5):625-34. PubMed ID: 12934177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 49. Gynecomastia in HIV-infected patients receiving antiretroviral therapy.
    García-Benayas T; Blanco F; Martín-Carbonero L; Valencia E; Barrios A; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):739-41. PubMed ID: 14585204
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
    Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The burden of gynecomastia among men on antiretroviral therapy in Zomba, Malawi.
    Singano V; Amberbir A; Garone D; Kandionamaso C; Msonko J; van Lettow M; Kalima K; Mataka Y; Kawalazira G; Mateyu G; Kwekwesa A; Matengeni A; van Oosterhout JJ
    PLoS One; 2017; 12(11):e0188379. PubMed ID: 29155891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
    AIDS Alert; 1998 Nov; 13(11):121-4. PubMed ID: 11365967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-associated lipodystrophy syndrome: LioN-HAART cohort: (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy.
    Lauenroth-Mai E; Schlote F
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):253-5. PubMed ID: 12394807
    [No Abstract]   [Full Text] [Related]  

  • 56. Efavirenz and retinal toxicity.
    Lewis A; Mitchell S
    Eye (Lond); 2002 Jan; 16(1):107. PubMed ID: 11913879
    [No Abstract]   [Full Text] [Related]  

  • 57. HIV-related neutropaenia exacerbated by efavirenz.
    Healy BJ; Freedman AR
    HIV Med; 2006 Mar; 7(2):129-31. PubMed ID: 16420258
    [No Abstract]   [Full Text] [Related]  

  • 58. Editorial comment: unraveling the cause of HIV-related gynecomastia.
    Braunstein GD
    AIDS Read; 2004 Jan; 14(1):38-9. PubMed ID: 14959702
    [No Abstract]   [Full Text] [Related]  

  • 59. [Apropos of atypical melancholia with Sustiva (efavirenz)].
    Lang JP; Halleguen O; Picard A; Lang JM; Danion JM
    Encephale; 2001; 27(3):290-3. PubMed ID: 11488260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.
    Alonso-Villaverde C; Coll B; Gómez F; Parra S; Camps J; Joven J; Masana L
    AIDS; 2005 Feb; 19(3):341-2. PubMed ID: 15718846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.